Introduction
Splenomegaly and/or chronic lymphadenopathy (lymphoproliferation) and autoimmune cytopenias are common clinical problems in different immunodeficiencies and constitute a diagnostic challenge 1 . A key differential diagnosis in patients with these clinical manifestations is the autoimmune lymphoproliferative syndrome (ALPS) 2 , which is caused by defects in the extrinsic FAS mediated apoptosis pathway 3, 4 . Due to advances in the immunological and genetic understanding of the disease [5] [6] [7] [8] , the diagnostic criteria and classification have recently been revised 9 . A definitive diagnosis of ALPS requires chronic lymphoproliferation and raised levels of CD3+TCRα/β+CD4-CD8-double negative T (DNT) cells plus one primary accessory criterion, i.e. either defective FAS mediated T cell apoptosis
in vitro or a somatic or germline mutation in the genes encoding FAS (ALPS-FAS and ALPSsFAS), FAS Ligand (ALPS-FASLG) or CASP10 (ALPS-CASP10). Patients who fulfill ALPS
diagnostic criteria with defective in vitro FAS induced apoptosis, in whom no causative mutation can be identified, are classified as ALPS-U. This leaves a significant proportion of patients with lymphoproliferation and autoimmunity unclassified (ALPS-phenotype:
lymphoproliferation with or without autoimmune cytopenia(s), raised DNT but normal apoptosis). The latter two patient groups may include rare cases with ALPS related diseases including CEDS (caspase 8 deficiency state) and RALD (RAS-associated autoimmune leukoproliferative disease).
Recently, a number of biomarkers including soluble FAS ligand (sFASL), IL-10 and vitamin B12 were shown to be specifically altered in ALPS patients 10,11 with a high positive predictive value for the presence of FAS mutations 12 . Consequently, as secondary accessory diagnostic criteria for ALPS, these markers have become part of a suggested algorithm for the diagnostic work-up of patients with suspected ALPS. This algorithm recommends FAS germline sequencing in all patients with lymphoproliferation and elevated DNT, while further analysis for somatic FAS mutations depends on the biomarker profile 9 .
Despite these important advances, a number of questions remain unresolved. In the study by Caminha et al. at the National Institutes of Health (NIH) 12 , the utility of biomarkers was retrospectively evaluated in a large cohort of ALPS-FAS, ALPS-sFAS, ALPS-U, ALPSphenotype patients as well as mutation positive and negative healthy relatives. It remains to be shown whether prospective analysis of an independent cohort can confirm their high predictive value. Moreover, patient selection was based on the criteria of chronic lymphoproliferation and raised DNT and thus biased by the a priori inclusion of raised DNT as a biomarker. It therefore remains unclear how the biomarkers perform in the initial laboratory evaluation of unselected patients with lymphoproliferation and autoimmune cytopenia(s). Moreover, a number of additional biological parameters such as memory B cells, sCD25, expression of B220 on DNT and serum lipids show characteristic alterations in ALPS, but have so far not been evaluated. If their high discriminatory value can be confirmed, this may allow using biomarkers for initial screening with a subsequent biomarkerbased decision on FAS sequencing. This could result in significant cost saving.
We therefore initiated a prospective study to evaluate the previously assessed as well as additional biomarkers for their ability to predict or exclude FAS mutations in a cohort of patients selected on the basis of their clinical presentation with splenomegaly and/or chronic lymphadenopathy and presumed or proven autoimmune cytopenia(s). We aimed to use the best identified biomarkers for development of a simple tool to calculate the individual probability of a FAS mutation prior to any other selection criteria such as DNT levels. Based on our prospective data, we propose vitamin B12 and sFASL determination as the first step in the diagnostic flow of patients with lymphoproliferation and autoimmune cytopenia(s) with a subsequent decision on FAS sequencing.
Methods

Patients
All patients presenting to one of the collaborating immunodeficiency centers with lymphoproliferation (defined as chronic non-malignant lymphadenopathy for > 6 months at more than 2 sites and/or splenomegaly) and presumed or proven autoimmune cytopenia(s)
were eligible for this study. Autoimmune cytopenia was defined as cell counts repeatedly below normal in one or more blood cell lineages with detectable autoantibodies. A number of patients with neutropenia or thrombocytopenia did not undergo autoantibody testing, but were diagnosed with presumed autoimmune cytopenia by the referring physician. The study was approved by the ethics committee of the University of Freiburg (protocol number 40/09).
Clinical chemistry, flow cytometry and apoptosis assay
Serum and EDTA blood was sent to the coordinating study center in Freiburg by overnight delivery and the following 11 parameters were determined in a single reference laboratory in all patients: vitamin B12 (Eclia: Electrochemiluminescence Immunoassay, Roche diagnostics), soluble CD25 (sCD25; turbidimetry), HDL cholesterol (HDL; homogenous enzymatic colour test, apolipoprotein A1 (APO-A1; turbidimetry), IgG (turbidimetry). Soluble FAS ligand (sFASL) and IL-10 were determined by ELISA as described 13 .
CD3+TCRα/β+CD4-CD8-double negative T (DNT) cells, the percentage of DNT cells expressing B220 (B220) and marginal zone like (CD19+CD27+IgD+IgM+, MZB) and class switched memory B cells (CD19+CD27+IgD-IgM-; SMB) were determined by flow cytometry as described 13, 14 . FASL induced apoptosis was analyzed as described 13 .
Genetic analysis
In patients with abnormal apoptosis, exons and exon-intron boundaries of the FAS gene were sequenced using DNA from granulocytes or whole blood. Figure 1) .
Biomarker profiling in patients with lymphoproliferation and autoimmune cytopenia(s)
We then analyzed the distribution of values for 11 biomarkers in the five patient categories (detailed information on missing values is provided in Supplementary Table 2 values, MZB and SMB were reduced in 90% and 86% of ALPS-FAS patients, respectively, and in 100% and 83% of ALPS-sFAS patients, compared to 56% and 78% of ALPS-U, 63%
and 88% in sequenced and 70% and 89% of not sequenced ALPS phenotype patients. IgG levels were above normal in 15/27(56%) and below normal in 3/27(11%) of ALPS-FAS patients. Elevated IgG was also observed in 17% of sequenced ALPS-phenotype patients, while 27% of not sequenced ALPS-phenotype patients had IgG levels below the age-related normal range. Biomarker values of patients with defined molecular diagnoses other than ALPS are shown in Supplementary Table 3 .
To investigate the potential of the single biomarkers to diagnose a FAS mutation, we determined AUC values for each biomarker (Table 2) vitamin B12 and sFASL were the best predictors of a FAS mutation and significantly better than DNT levels (p=0.006, p=0.012, respectively). Comparison to the available published AUC values in the NIH study showed that sFASL performed in a similar way to the NIH study, DNT slightly worse while vitamin B12 and IL-10 performed significantly better (p<0.01, p=0.04 respectively).
Positive and negative predictive values of biomarker combinations for the diagnosis of ALPS-FAS
Subsequently, we analyzed the predictive values of the determined biomarkers. In order to facilitate comparison between the studies, we first used cut-off values and combinations suggested by Caminha et al. 12 (Table 3A) . In our cohort with a prevalence of FAS mutations of 39%, vitamin B12 (>1500 pg/ml), sFASL (>300 pg/ml) or IL-10 (>40 pg/ml) alone identified between 27%, 44% and 43% of the patients with predictive values of 87%, 81% and 73%, respectively. In contrast, DNT (>4%) only reached a PPV of 63%, although it identified a patient group of similar size (34%). The PPV of DNT was significantly lower compared to the NIH study (p<0.001). Combination of vitamin B12 and sFASL led to a PPV of 95% and still identified a group of 25%. Combining DNT with vitamin B12 or sFASL, also yielded PPVs above 90%, but identified fewer patients (Supplementary Table 4A ).
Looking at the prediction of the absence of a FAS mutation (Table 3A) , sFASL (<200 pg/ml) had a negative predictive value of 97% and identified 43% of all patients. Vitamin B12 (<1000 pg/ml) and IL-10 (<20 pg/ml) identified slightly larger groups and had NPVs of 91%, which were significantly higher compared to the NIH study (p<0.001 for both). DNT (<2%) had a NPV above 70% and identified only a third of all patients. Combining sFASL and vitamin B12 identified a group of similar size and with a NPV of 100%. Combining DNT with sFASL and vitamin B12 identified fewer than 25% of the patients. (Supplementary table 4B) One of the problems of the cut-off values defined by Caminha et al. 12 was that they covered highly variable fractions of our population. For example, while 44% of our population had elevated sFASL levels above 300 pg/ml, only 27% had elevated vitamin B12 levels above 1500 pg/ml. In a second step, we therefore considered a different set of cut-off values that were chosen according to the FAS mutation prevalence in our cohort leading to identification of 40% of the patients as positive and 60% as negative (Table 3B) . Using these cut-offs (sFASL 559 pg/ml, vitamin B12 1255 pg/ml, DNT 3.8%) the best biomarkers were sFASL (PPV 84% and NPV 94%) followed by vitamin B12 (PPV 73% and NPV 88%), while DNT performed much worse (PPV 61%, NPV 77%). Using biomarker combinations, vitamin B12
and sFASL above these cut-offs identified 29% of our population with a PPV of 92%, while both values below these cut-offs identified 49% of the population with a NPV of 97%. Other biomarker combinations did not perform better (Supplementary Tables 4C and 4D) .
Combining the more easily available biomarkers vitamin B12, HDL and APO-A1 yielded a PPV of 83% and identified 15% of our population. When these three values were below the cutoffs, 36% were identified with a NPV of 90%.
Using biomarker combinations to re-evaluate the results of genetic analysis
The high AUC values of the single markers and the high positive and negative predictive values observed for some marker combinations suggested that these biomarkers can nearly separate the group of FAS mutation positive from the group of FAS mutation negative patients. This is illustrated by a scatter plot of vitamin B12 against sFASL with marking of the five considered patient categories (Figure 2 ). ALPS-FAS/sFAS patients were well separated from patients with chronic lymphoproliferation and presumed or proven autoimmune cytopenia(s) of unknown molecular origin. Of note, in our original dataset there were 5 individuals among ALPS-U and ALPS-phenotype patients, who had a biomarker profile highly suggestive of a FAS mutation, with both vitamin B12 and sFASL values above the cut offs of 1255 and 559 pg/ml, respectively. We carefully re-evaluated the original genetic findings in these patients. In one patient, a misnaming of samples was uncovered and the patient was reclassified as ALPS-sFAS. In another patient, two initial cell sortings did not yield sufficient numbers of DNT cells, and only when a third sample was sent, the genetic analysis could be completed revealing ALPS-sFAS. These two patients were reclassified prior to the analyses presented in this paper and are marked with arrows in Figure 2 . One patient with familial ALPS-U had reduced FAS expression on T cell subsets (not shown),
suggesting a disturbed regulation of FAS expression. Two patients had their DNT reanalyzed but no mutation could be identified.
A biomarker-based probability calculator for selection or exclusion of patients with lymphoproliferation and autoimmunity to undergo FAS sequencing
As the best single markers were already highly predictive and the size of our population was limited, it was not possible to determine optimal scores combining several markers using methods like logistic regression. To combine the information from single markers, we therefore used the naïve Bayes classification approach, which is based on the assumption of conditional independence of the markers given the FAS gene status, but is also known to be rather robust against violations of this assumption 17, 18 . This approach makes use only of the means and standard deviations of each marker in FAS mutation-positive and FAS mutationnegative patients and allows computing the probability of a patient with lymphoproliferation and presumed or proven autoimmune cytopenia(s) to carry a FAS mutation based on measurements for any set of markers. Based on this algorithm, we have created a webbased tool (Figure 3) , where clinicians can enter the values for vitamin B12, sFASL and IL-10 of their patients to estimate the probability of underlying FAS mutations (http://www.alps.unifreiburg.de/). We included IL-10 to allow a more flexible use of the tool. In particular, it will enable retrospective validation of the tool with patients who did not have the two best biomarkers determined. It is important to note that calculated probabilities are only estimates which are clinically useful for selection of patients with high (>95%) versus low (<5%) FAS mutation probability. Values between 5 and 95% can only exclude high or low risk of a FAS mutation but do not represent reliable estimates of FAS mutation probability.
Although validation of the tool and diagnostic path need to be carried out on different data sets in the future, we analyzed the distribution of the individual probabilities according to this tool in our population in order to check whether the general robustness of the naive Bayes classifier holds in our situation. If not, this should become visible by such an analysis. ALPS-U patients were excluded from this evaluation as their biomarker values fit into either of the ALPS-FAS or ALPS-ph groups. When the probability of FAS mutation was calculated using the three strongest predictors vitamin B12, sFASL and IL-10, we observed that 35% of the study population had a high probability (>95%), of whom 83% actually had the FAS mutation; 56% had a low probability (<5%) with only 2% carrying a FAS mutation.
Discussion
In this prospective study on patients referred for the diagnostic evaluation of chronic lymphoproliferation and presumed or proven autoimmune cytopenia(s), we evaluated 11 biomarkers in the diagnosis of ALPS. Our results suggest determination of vitamin B12 and sFASL with subsequent decision on FAS sequencing as the most efficient and cost-effective diagnostic pathway to establish a molecular diagnosis. The positive and negative predictive values determined in this study were integrated into a simple web-based probability calculating tool that can support the decision whether or not to perform FAS sequencing based on any combination of values for the best predictive biomarkers IL-10, sFASL and vitamin B12.
Lymphoproliferation and autoimmune cytopenia(s) are common manifestations of impaired immune regulation and are frequently associated with primary immunodeficiencies, including, but not limited to ALPS. When conceiving our study, we reasoned that a prospective evaluation of diagnostic laboratory parameters could best be performed in an unselected cohort referred for a combination of clinical symptoms rather than in patients preselected for biological markers such as DNT cells. This approach should provide the most relevant disease population for this particular clinical situation. However, this implies that our study does not provide information on patients referred for the evaluation of lymphoproliferation or autoimmune cytopenia alone or in combination with other autoimmune manifestations or with DNT elevation. In fact, during the time of the study, we also evaluated 23 other patients who did not fulfill our clinical entry criteria and identified FAS mutations in 12 (11 germline, 1 somatic). It is important to be aware of this conceptual difference when discussing our findings in relation to the landmark studies of Magerus-Chatinet et al. 10 and Caminha et al. 12 .
Despite these differences in study concepts, we could confirm the high predictive value of vitamin B12, sFASL and IL-10 for the presence of FAS mutations in an independent, prospectively evaluated European cohort. Positive and negative predictive values were best for sFASL, IL-10 and vitamin B12 as single markers and best for vitamin B12 and sFASL as a biomarker combination. Obviously, positive and negative predictive values of biomarkers critically depend on the definition of cut-offs, but the cut-offs defined by Caminha et al. 12 and the cut-offs generated in our cohort yielded similar results. Of note, single biomarkers performed better in exclusion of FAS mutation in our cohort than in the study by Caminha et al. 12 . Although the different size of the study populations may also be a relevant factor, this is most probably related to the different structure of the patient cohorts with important implications for the calculation of predictive values. Thus, the percentage of patients with FAS mutations among all symptomatic patients was much higher (171 of 263, i.e. 65%) than in our study (38 of 98, i.e. 39%), which may be related to the fact that the retrospective study by Caminha et al. 12 was performed in a dedicated ALPS referral center. Moreover, the inclusion of healthy relatives in the control group of that study 12 represents a significant difference to our approach of only considering symptomatic patients.
The most relevant difference between the two studies was observed in the diagnostic value of DNT cells. When we initiated the study, DNT were defined as CD4-CD8-of CD3+TCRα/β+ cells among peripheral blood mononuclear cells (PBMC) using a threshold >1%. New guidelines recommend whole blood staining and thresholds of CD4-CD8-TCRα/β+ of CD3+ cells >2.5% or CD4-CD8-TCRα/β+CD3+ of lymphocytes >1%. Following publication of these guidelines we performed both our initial as well as the recommended staining in all patients.
In comparison, DNT values determined using the suggested protocol 9 were slightly higher than those determined with our protocol. This is of limited impact for the results because it equally affected patients and controls. Since we did not have full blood stains for all recruited patients, we used the data obtained with our initial protocol for this analysis. DNT of CD3+/TCRα/β+ were raised above 1% in 92% and above 2% in 69% of disease control patients who did not carry FAS mutations. Since the proportion of disease controls was higher in our study, the predictive value of DNT determinations was much lower than in the study by Caminha et al 12 .
Only when greater than 8%, DNT levels were reliably associated with a FAS mutation. In patients with chronic lymphoproliferation and autoimmune cytopenia(s), DNT levels therefore appear no more useful than the panel of additional biomarkers that were tested in our study including sCD25, serum lipids, memory B cells 13 and B220 expression on DNT cells 14 . Although characteristic alterations of these markers were observed in most patients with FAS mutations, they were similarly elevated or reduced in significant proportions of disease control groups, reducing their predictive value. It is relevant to note that the combination of the more easily available markers vitamin B12, HDL and APO-A1 could exclude FAS mutation with a probability of 90% in 36% of our cohort (Supplementary Table 4D ). However, the addition of any one of the other 9 markers considered in our analyses to sFASL and vitamin B12 did not improve the positive or negative predictive values.
Interestingly, as observed previously 12 , some individuals among ALPS-U and ALPSphenotype patients had biomarker profiles highly suggestive of a FAS mutation. Given the high specificity of these markers, we hypothesized that they may have been misclassified or require more extensive genetic analysis. Indeed, two of these five patients were eventually reclassified as ALPS-sFAS (Figure 2 ). In the other three, the characteristic biomarker profile could point to a more complex affection of FAS expression/function or to yet unknown defects in the FAS pathway; these patients are currently analyzed for splice site and intronic FAS mutations, two have undergone whole-exome sequencing.
Another important issue in the diagnostic evaluation is the stability of biomarkers over time. It has been observed previously that sFASL, IL-10 and DNT decrease in response to immunosuppressive therapy 10 . We have therefore performed additional analyses separating untreated patients (n=58) from treated patients (n=32) in our cohort (Supplementary Table   4 ). Overall, positive and negative predictive values were comparable in untreated versus treated patients. However, a clear decrease of the positive predictive value in treated patients was seen for DNT. The variability of biomarkers in the long-term course of the disease and in response to different treatment regimen after initial diagnosis as well as their potential predictive impact on clinical outcome are additional relevant issues that need to be addressed in continued diagnostic and follow-up studies.
The identification of biomarkers which are specifically raised in FAS mutant patients by Magerus-Chatinet et al. 10 and Caminha et al. 12 have very usefully extended the ALPS diagnostic panel and have been integrated into a revised diagnostic algorithm. This revised algorithm proposes germline sequencing in all patients with lymphoproliferation and raised DNT and makes use of biomarkers for subsequent selection of patients who require additional DNT sorting in search for somatic FAS mutations. Our results suggest that for the diagnostic evaluation of patients presenting with chronic lymphoproliferation and autoimmune cytopenia(s), an alternative diagnostic pathway can be followed. We propose initial determination of vitamin B12 and sFASL in order to decide who will need FAS sequencing.
We still include analysis of DNT in the initial screening, but mainly to quantify their surface FAS expression, which can be helpful to identify patients with somatic second hit mutations 19, 20 . The combination of vitamin B12 and sFASL helps to identify both patients with germline as well as somatic FAS mutation and possibly also patients with as yet unknown mutations in the FAS pathway ('ALPS by biomarkers'). Moreover, it can render FAS mutations highly unlikely in a large proportion of patients with lymphoproliferation and autoimmunity.
Based on these data, it is our current policy to enter vitamin B12 and sFASL values into the probability calculator and if the probability is <5% (low risk), we do not sequence FAS. If clinical suspicion remains in the further clinical course, biomarkers are determined again, since they can vary. If the calculated probability is >95% (high risk), we proceed to germline FAS sequencing and, if this is negative, we sequence DNA from sorted DNT cells. In patients with a probability between 5 and 95%, we base the decision on FAS sequencing on DNT levels and apoptosis induction: If both are normal, we do not sequence FAS, but if either 18 DNT are above 3.8% or apoptosis is defective or both we proceed to FAS sequencing from germline and/or DNT DNA. The results of applying this algorithm retrospectively to our cohort for estimation of robustness of the calculating tool are shown in Supplementary Figure 4 .
This sequential diagnostic approach must be validated prospectively in independent patient cohorts. The online calculator tool developed in this study will contribute to this evaluation.
Thus, our findings provide additional prospective information and can contribute to evolving consensus recommendations addressing diagnostic algorithms in patients with lymphoproliferation and autoimmune cytopenia(s).
The spectrum of other genetic diseases identified in our cohort reflects the large differential diagnosis in patients with chronic lymphoproliferation and autoimmune cytopenia(s). To date the majority of these patients remain without genetic diagnosis. One important challenge for future studies is to better define a rational diagnostic approach to these patients. This includes algorithms to select those in whom FASL, CASP8 or 10 or K/N-RAS mutations must be stringently looked for, both on a germline as well as on a somatic level. Table 3B ( Any number of the three most discriminative biomarkers vitamin B12, sFASL and IL-10 can be entered to calculate the individual probability of having a FAS mutation.
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